EGFR and non-small cell lung carcinoma: Somatic, activating mutations in the tyrosine kinase domain of EGFR are present in about 15% of Caucasian and nearly 50% of Asian patients with advanced NSCLC.1,2 Almost 90% of these mutations consist of deletions in exon 19 or L858R point mutations within exon 21.